Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

Area of Science:

• Cardiology
• Autonomic Neuroscience
• Medical Devices

Background:

• Heart failure (HF) is characterized by autonomic dysfunction, including increased sympathetic and decreased vagal activity.
• This imbalance contributes to disease progression and poor prognosis in HF patients.
• Baroreflex activation therapy (BAT) is a potential intervention to modulate autonomic activity.

Purpose of the Study:

• To evaluate the efficacy of Baroreflex activation therapy (BAT) in patients with NYHA functional class III heart failure (HF).
• To assess the impact of BAT on autonomic nervous system activity, clinical outcomes, and biomarkers in HF.

Main Methods:

• A pilot study involving 11 NYHA class III HF patients demonstrated BAT's effects over 21 months.
• A multinational, prospective, randomized, parallel-controlled trial included 146 NYHA functional class III HF patients.
• Measurements included muscle sympathetic nerve activity, hospitalizations, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

Main Results:

• BAT led to a persistent reduction in muscle sympathetic nerve activity and a significant decrease in hospitalizations in the pilot study.
• In the larger trial, BAT significantly reduced NT-proBNP levels (p=0.02).
• A trend towards fewer hospital days for HF was observed with BAT.

Conclusions:

• BAT effectively inhibits cardiac sympathetic outflow and enhances vagal activity through a physiological reflex.
• BAT demonstrates potential as a therapeutic tool to correct autonomic imbalances in advanced HF.
• BAT may significantly improve prognosis for patients with advanced heart failure by addressing autonomic dysfunction.